Narrative review proposes senescence-linked cardiac lymphatic dysfunction in HFpEF
This narrative review proposes, but does not test, a framework in which cellular senescence and its senescence-associated secretory phenotype impair cardiac lymphatic function, amplifying the edema, inflammation and fibrosis described in heart failure with preserved ejection fraction. [1]
Automatic summary · not editorially reviewed
The key findings
The review proposes that cellular senescence and its senescence-associated secretory phenotype impair cardiac lymphatic function, amplifying edema, inflammation and fibrosis in HFpEF. [1]
The authors describe HFpEF as the dominant and most therapeutically recalcitrant heart failure phenotype, with incompletely delineated pathophysiology. [1]
The synthesis is intended to stimulate interdisciplinary investigation and provide a conceptual scaffold for future clinical trials. [1]
The source at a glance
- Study type / format
- Narrative review (abstract)
- Population / context
- People with heart failure with preserved ejection fraction, discussed as a predominantly elderly and comorbid patient population.
- Summary based on
- Study abstract
- Original publication
- August 8, 2026
Proposed senescence-lymphatic axis in HFpEF
The review describes heart failure with preserved ejection fraction (HFpEF) as the dominant and most therapeutically difficult heart failure phenotype today, with incompletely understood pathophysiology. It advances a mechanistic framework: cellular senescence, and specifically its main paracrine effector, the senescence-associated secretory phenotype (SASP), is proposed to drive progressive impairment of cardiac lymphatic function. That impairment is proposed to amplify the myocardial interstitial edema, chronic inflammation and fibrotic remodeling that define HFpEF. The authors call this a previously underappreciated but mechanistically compelling axis.
Supporting source [1]
Synthesis from geroscience, lymph biology and cardiac physiology
The authors state that they critically synthesize emerging evidence from molecular geroscience, lymphatic biology and cardiac physiology. On that basis they argue that SASP-driven lymphatic endothelial dysfunction is an underappreciated axis in HFpEF pathobiology. The abstract reports no new experiments, participants, follow-up or measured outcomes; it presents an argument built from existing literature rather than a test of the proposed mechanism.
Supporting source [1]
Translational ideas and stated obstacles, not tested treatments
The review discusses translational implications, including the therapeutic potential of senolytic and senomorphic interventions. It also names obstacles in cardiac lymphatic imaging and targeted drug delivery, and ethical considerations around antiaging strategies in a predominantly elderly and comorbid patient population. The authors intend the synthesis to stimulate interdisciplinary investigation and serve as a conceptual scaffold for future clinical trials targeting the senescence-lymphatic interface. These are proposals and discussion points, not demonstrated benefits or validated treatments.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. This is a narrative review proposing a framework, not an experimental or clinical study, so the proposed mechanism and any treatment potential remain untested here.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.